Lepu Biopharma Co., Ltd.
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS10
PHASE 3 / 2-33
RECRUITING7
READOUTS ≤12 MONTHS2
READOUT SLIPPED >6 MO50%
Delay Index: of 6 active trials registered more than a year ago, 3 have moved their primary completion (readout) date by more than 6 months since first registration (median +22.0 months). See all sponsors →
Open Lepu Biopharma Co., Ltd. on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| MRG003 NCT05126719 |
P2 | Active, not recruiting | Recurrent or Metastatic Nasopharyngeal Carcinoma | 238 | 2024-12-30 (+22 mo) |
| MRG004A plus best supportive care NCT07138846 |
P3 | Not yet recruiting | Advanced Pancreatic Cancer | 231 | 2027-06 |
| MRG003+HX008 NCT05688605 |
P1/2 | Recruiting | Advanced Solid Tumors | 18 | 2027-08 (+27 mo) |
| MRG003 NCT05751512 |
P3 | Recruiting | Squamous Cell Carcinoma of the Head and Neck | 180 | 2027-12 (+28 mo) |
| MRG006A NCT07093970 |
P1/2 | Recruiting | Advanced Solid Tumors | 343 | 2027-12 |
| Becotatug Vedotin for Injection NCT07586124 |
P2 | Recruiting | Head and Neck Squamous Cell Carcinoma | 80 | 2027-12 |
| Cretostimogene Grenadenorepvec NCT07283835 |
P2 | Recruiting | Non Muscle Invasive Bladder Cancer; High-grade Ta/ T1 Papillary Disease Bladder Cancer | 16 | 2027-12-31 |
| MRG006A NCT07479485 |
P1/2 | Recruiting | Hepatocellular Carcinoma | 160 | 2028-04 |
| MRG007 NCT07737600 |
P1/2 | Not yet recruiting | Advanced Colorectal Cancer | 316 | 2028-12 |
| Magic-C002 NCT06976190 |
P3 | Recruiting | Recurrent or Metastatic Nasopharyngeal Carcinoma | 446 | 2029-05 |